Showing results (61-70 of 541) with videos related to

Sort By:
Pageof 55
Liver Cancer|October 26, 2013
Intraoperative ultrasound in patients with hepatocellular carcinoma: from daily practice to future trendsMatteo Donadon, Guido Torzilli
Liver Cancer|October 26, 2013
Local ablation for hepatocellular carcinoma in taiwanShi-Ming Lin
Liver Cancer|October 26, 2013
Hepatic progenitor cells: their role and functional significance in the new classification of primary liver cancersRegina Cheuk-Lam Lo, Irene Oi-Lin Ng
Liver Cancer|March 23, 2026
Machine Learning Models for Disease-Free Survival Analysis after Liver Resection for Hepatocellular Carcinoma: A Multicentric French Collaborative StudyRami Rhaiem, Ammar Abdo, Julien Calderaro, et al.
Liver Cancer|April 13, 2026
Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-Label, Randomized, Phase 3 TrialStephen Lam Chan, Ahmed Omar Kaseb, Laura Alexander, et al.
Liver Cancer|April 13, 2026
Multidisciplinary Clinic Approach Improves Immunotherapy Treatment Outcomes in Unresectable Hepatocellular Carcinoma: A Multicentre Retrospective StudyAndrea Dalbeni, Alessandra Auriemma, Marco Vicardi, et al.
Liver Cancer|June 3, 2026
Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety StudyJing-Kun Chen, Jia-Liang Wei, Zhen-Dong Yang, et al.
Liver Cancer|June 16, 2023
Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and SafetyPhilippe Merle, Masatoshi Kudo, Stanimira Krotneva, et al.
Liver Cancer|May 27, 2026
An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final AnalysisMarkus Peck-Radosavljevic, Akhmed Abdelgafur, Alessandro Granito, et al.
Liver Cancer|May 29, 2026
Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma with and without High-Risk Features: An International Multicenter StudyJung Sun Kim, San-Chi Chen, Jeffrey Sum Lung Wong, et al.
Pageof 55